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Abstract
Despite improvements in neonatal intensive care, neonatal bacterial meningitis 
continues to be a serious disease with mortality rates varying between 10 and 15%. 
Additionally, long-term complications are observed among 20–50% of survi-
vors, depending on time of diagnosis and therapy and virulence of the infecting 
 pathogen. It is more common during the neonatal period than at any other age with 
the estimated incidence of 0.25 per 1000 live births. The absence of specific clinical 
presentation makes diagnosis of meningitis more difficult in neonates than in older 
children. Culture of cerebrospinal fluid is the traditional gold standard for diagno-
sis of bacterial meningitis, so all newborn infants with proven or suspected sepsis 
should undergo lumbar puncture. However, deciding when to perform lumbar 
puncture and interpretation of the results are challenging. Although the patho-
physiology of neonatal meningitis is complex and not fully understood, researches 
on diagnostic and prognostic tools are ongoing. Prevention of neonatal sepsis, early 
recognition of infants at risk, development of novel, rapid diagnostics and adjunc-
tive therapies, and appropriate and aggressive antimicrobial treatment to sterilize 
cerebrospinal fluid as soon as possible may prevent the lifelong squeal of bacterial 
meningitis in newborn infants.
Keywords: neonate, meningitis, diagnosis, treatment, outcome
1. Introduction
Along with the Millennium Development Goals, under-5 mortality rate reduced 
by an impressive 53% globally, from 1990 until 2015 [1]. Forty-five percent of 
under-5 mortality now occurs in the first month of life. Besides intrapartum causes 
and preterm birth complications, infections are one of the leading causes of neona-
tal deaths [2]. Neonatal sepsis and meningitis are collectively responsible for 6.8% 
of the global under-5 deaths [3].
Neonatal meningitis is a devastating disease associated with significant mor-
tality and morbidity in both developed and developing countries. The improve-
ments in healthcare delivery systems over the last several decades, especially in 
developed countries, resulted in a decline in mortality, but the rate of neurological 
morbidities in infants who survive remains substantial and ranged from 20 to 50% 
[4–8]. However, the incidence and mortality of neonatal meningitis in developing 
 countries remain unacceptably high, variably reported as 0.8–6.1 per 1000 live 
births and 40–58%, respectively [7].
Bacterial meningitis is more common in the neonatal period than at any other 
time, with higher incidence in preterm and chronically hospitalized infants [9–11]. 
Additionally, the epidemiology of bacterial meningitis, the corresponding patho-
gens, the immature immune system and its response to infection and outcomes are 
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distinctive to the neonatal period [12, 13]. A cerebral insult related to meningitis has 
a greater impact on the vulnerable, developing brain, so a younger age during dis-
ease is usually associated with a poorer outcome [14]. Therefore, overall improved 
recognition, evaluation, and aggressive antimicrobial treatment of bacterial 
meningitis in newborn infants are essential to lead to a reduction in the mortality 
and the lifelong squeals.
This chapter will focus on the epidemiology, etiology, pathogenesis, diagnosis, 
treatment, and outcome of neonatal bacterial meningitis.
2. Definition
Meningitis is defined as infection and inflammation of the meninges, subarach-
noid space and brain vasculature [15]. Since epidemiology of neonatal meningitis 
is similar to that of neonatal sepsis, neonatal meningitis is also divided into early-
onset and late-onset meningitis, based on timing of infection and presumed mode 
of transmission [16, 17]. The cutoff for these definitions is variable throughout 
the literature. Early-onset meningitis is typically defined as meningitis occurring 
within the first 3 or 7 days after birth, and especially those in the first 2 days after 
birth reflect vertical transmission of invasive organism from maternal genital tract 
flora. Late-onset meningitis is usually defined as infection occurring as early as 4 or 
8 days after birth and as late as 28 days after birth, and it is attributed to organisms 
acquired from interaction with the hospital environment or the community [16–18]. 
In very low-birth weight preterm and high-risk term infants, many of whom have 
prolonged hospital stays, the description of late-onset meningitis may be applicable 
until hospital discharge regardless of the age at the time of the infection [16]. The 
distinction between two patterns is useful to guide therapy. However, this distinc-
tion does not necessarily be valid in the developing world, where unsanitary birth 
practices and newborn care at home or in hospitals confront newborns with the risk 
of acquiring environmental pathogens at or soon after birth [19, 20].
3. Epidemiology
Worldwide, the incidence of neonatal bacterial meningitis is between 0.22 and 
2.66 per 1000 live births. However, the incidence varies by countries of different 
income levels [11, 20–22].
The incidence of culture-proven neonatal meningitis is estimated between 
0.21 and 0.3 per 1000 live births in developed countries [4, 11, 23]. This number is 
probably underestimated since a lumbar puncture is not performed in up to 50% of 
infants who were evaluated for sepsis in the intensive care nursery [4], and when it 
is performed, it may be done after the initiation of antibiotics, likely biasing culture 
results [4, 24]. The incidence in very-low-birth weight (VLBW) infants may be as 
high as 1.4%, and about 5% of those with at least one lumbar puncture performed 
during the hospital stay suffer from late-onset meningitis [25]. Bacterial meningitis 
occurs in 25% of neonates with bacteremia [17], whereas in LVBW infants with 
meningitis, the rate of blood culture positivity is as much as 55% [25].
In developed countries, mortality from neonatal meningitis was nearly 50% in 
the 1970s, and then it has dropped to figures ranging from 10 to 15% [5, 7, 26–29]. 
However, long-term sequelae rates did not change, with up to 50% of survivors hav-
ing long-term neurodevelopmental complications [4–8, 27]. In a prospective study 
including 444 cases of confirmed meningitis during 2001–2007, it was reported 
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that the case fatality for neonatal bacterial meningitis was 13%, but much higher in 
preterm babies (25%) [29].
It may be difficult to estimate the incidence in developing countries due to 
under-developed surveillance systems. A few community-based studies published 
from developing countries tend to reveal higher incidence of neonatal meningitis 
[20]. In these studies, the incidence of neonatal meningitis in the first week of 
life ranged from 0.8 to 6.1 per 1000 live births [4, 5, 20]. In developing countries, 
mortality from neonatal meningitis ranges from 40 to 58% [7]. It is very likely that 
most of the studies from developing countries have biases in selection of study 
population, which may have underestimated true incidence rates. Additionally, the 
lack of laboratory-based confirmation as well as varied clinical criteria and access 
to health care facilities and limited resources may lead to underreporting in these 
regions [20].
The most common organisms associated with neonatal meningitis are Group B 
Streptococcus (GBS), Escherichia coli, and Listeria monocytogenes, and GBS and  
E coli account for approximately two-thirds of all cases of neonatal meningitis [8, 
30]. Thanks to the program consists of identifying pregnant women who are GBS 
carriers by screening and/or identifying the presence of risk factors that predispose 
the infants to infection, the incidence of early onset neonatal GBS sepsis in the 
United States has declined from 1.5 per 1000 live birth to 0.3 per 1000 live births. 
However, the incidence in late onset neonatal GBS infection appears to remain 
unchanged or even increasing [30–35]. Additionally, there is an increased incidence 
of Gram-negative bacteria, specifically antibiotic-resistant E coli, in early-onset 
infection in the preterm and VLBW infants [30].
4. Etiology
The types and distribution of organisms that commonly cause neonatal menin-
gitis depend on age at presentation, location, and gestational age. The distribution 
of organisms observed in neonatal meningitis is similar to that of neonatal sepsis 
(Table 1) [4, 18, 23]. So, meningitis may be a component of early-onset, late-onset, 
and nosocomial infection.
The group B streptococcus (especially capsular serotype III) is the major 
causative pathogen, implicated in up to 50% of cases. Late-onset GBS sepsis is 
more likely to be complicated by meningitis when compared to early-onset GBS 
Causative pathogen
Group B Streptococcus
Other streptococci and staphylococci (including especially group D streptococci, Streptococcus pneumoniae, 
Staphylococcus epidermidis†, and Staphylococcus aureus)
Escherichia coli
Other Gram-negative enteric bacteria (including Pseudomonas aeruginosa, Klebsiella and Enterobacter species, 
Proteus species, Citrobacter species, and Serratia marcescens)
Others (including Haemophilus influenzae, Salmonella species, and Flavobacterium meningosepticum)
Listeria monocytogenes
For more, see Ref. [18]. 
†Coagulase-negative staphylococci are particularly common etiologies in very-low-birth-weight infants with late-
onset meningitis.
Table 1. 
Bacteria causing neonatal meningitis in developed countries.
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sepsis [36]. Colonization of the neonate with GBS may be acquired from maternal 
genital tract during delivery or from nosocomial sources [17]. The attack rate of the 
colonized newborn is approximately 1%. The risk factors that influence the attack 
rate include prematurity, dose and virulence of the organism, prolonged duration 
of ruptured membrane prior to the delivery, and maternal fever during labor [31]. 
Despite intrapartum antibiotic prophylaxis (IAP) to reduce vertical transmission of 
GBS infection, not all cases of early-onset GBS are prevented, and GBS continues 
to be the most common cause of early-onset disease in term neonates [4, 21, 37]. 
However, it is uncommon in developing countries, even if the prevalence of coloni-
zation in women has been reported as high as 22% and implementation of IAP is not 
possible [16, 38].
Escherichia coli is the second most common pathogen and represents 50% of 
gram-negative bacteria which account for 30–40% of cases of neonatal meningi-
tis [4, 11, 30]. Most of E coli (80%) strains causing meningitis possessed the K1 
polysaccharide capsular antigen which inhibits phagocytosis and resists antibody-
independent serum bactericidal activity [39, 40]. With the implementation of IAP 
against GBS, E Coli has emerged as the most common cause of early-onset sepsis 
and meningitis among VLBW infants [41, 42], and it has become the leading cause 
of sepsis-related mortality in this weight group [43]. Additionally, there is a grow-
ing concern on emerging antimicrobial resistance in E coli infections [41]. Klebsiella 
spp. are the second most important Gram-negative bacteria causing neonatal 
meningitis, especially in developing countries [4, 7]. The other Gram-negative 
organisms less commonly isolated include Enterobacter spp., Pseudomonas aerugi-
nosa, Citrobacter spp., and Serratia spp. [17]. Citrobacter spp. are usually associated 
with brain abscesses, emphasizing the importance of brain imaging as part of the 
evaluation whenever Citrobacter is isolated from the CSF [23].
It has been estimated that Listeria monocytogenes accounts for approximately 
5–7% of cases of neonatal meningitis [5, 28], since the incidence of neonatal Listeria 
infections has decreased substantially in recent years [44]. It continues to be impor-
tant in contribution to significant morbidity and mortality because of its association 
with thrombo-encephalitis. Similar to GBS neonatal infections, early-onset Listeria 
disease is often sepsis whereas late-onset Listeria disease is often meningitis [45]. 
Listeria serotype IVb is responsible for almost all cases of meningitis caused by 
this organism [46]. Listeria may be acquired following placental invasion during 
pregnancy, passively during the birth process or following horizontal transmission 
from environmental sources [17, 45].
Coagulase-negative staphylococcus (CNS) and Staphylococcus aureus are com-
monly seen in very premature and high-risk neonates who require prolonged 
hospitalization, central venous catheters, external devices and ventilator support 
[5]. Other less common but important pathogens associated with neonatal men-
ingitis include enterococcus, Streptococcus pneumoniae, Neisseria meningitidis, and 
Haemophilus influenzae [8, 18, 21]. Moreover, there is a wider range of more unusual 
and potentially antibiotic-resistant organisms causing late-onset meningitis in 
hospitalized patients [11, 18, 47–49].
5. Pathogenesis
Meningitis most commonly results as a consequence of hematogenous dissemi-
nation of bacteria via choroid plexus and cerebral microvasculature into the central 
nervous system during the course of sepsis [4, 15]. Rarely, meningitis may develop 
following the spread of an infection in the scalp or skull, and a contamination of 
open neural tube defect, congenital sinus tract, or ventricular device [4, 18, 50]. 
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The early- and late-onset patterns of the disease have been associated with sepsis 
during the first month of life, as invasion of the meninges occurs in as many as 
25% of infants with bacteremia [23, 50]. So, meningitis and sepsis typically share a 
common cause and pathogenesis.
Neonates are the most vulnerable of all age groups to infectious pathogens, 
because of immaturity of the immune system, as well as decreased placental passage 
of maternal antibodies, especially in preterm infants [16, 37]. All limitations of 
both initiate and adaptive immunity, decreased inflammatory and immune effec-
tor responses, and the deficient expression of complement and of antimicrobial 
proteins make fetus and neonate, particularly the premature neonate, susceptible to 
a wide variety of microorganisms [18, 51]. In addition to host susceptibility, obstet-
ric and nursery practices, socioeconomic status, and the health and nutrition of 
mothers are important in determining neonates at risk for infection, and similarly, 
in the pathogenesis of neonatal sepsis and meningitis [18, 37].
Initial colonization of the neonate usually occurs in utero from ascending 
bacteria entering the uterus from vaginal environment after rupture of amniotic 
membranes [18, 37]. If delivery is delayed, microbial invasion of amniotic fluid 
may cause an acute inflammation of the fetal membranes, which is defined as 
chorioamnionitis [18, 37]. Infected amniotic fluid may lead to fetal systemic 
inflammatory response syndrome, stillbirth, preterm delivery, or neonatal sepsis 
following invasion of bacteria into the fetus through respiratory tract (fetal breath-
ing), gastrointestinal tract (swallowing), skin, and ear [52]. Additionally, the 
neonate may be colonized with potentially pathogenic bacteria through the birth 
canal during delivery. Microorganism acquired by the neonate just before or during 
birth colonizes the skin and mucosa of multiple sites including the nasopharynx, 
conjunctivae, oropharynx, umbilical cord, and in the female infant, the external 
genitalia. Microorganisms can invade through any site where skin or mucosal 
barrier is disrupted [15, 17]. Bacteria may proliferate at the initial site of attachment 
without causing serious illness, or then, pass into the subepithelial blood vessel 
from where they can be transported to other parts of the body including the CNS 
[15, 18]. Transplacental hematogenous infection is also possible. Listeria monocy-
togenes is usually acquired transplacentally [4, 45]. In rare cases, hematogenous 
transmission of GBS, S pneumoniae, and N meningitidis from maternal bacteremia 
has been reported as causes of early-onset neonatal meningitis [18, 37, 53].
As infants grow up, they are exposed to environmental microorganisms that 
might be pathogenic to them. Poor hand hygiene among caregivers and hospital 
personnel, nutritional sources, and contaminated equipment all can transfer 
microorganism from infected infants to uninfected infants [13, 37, 53]. Most VLBW 
and high-risk infants have one or more procedures that expose them to risk of infec-
tion during their hospital stay. Invasive devices such as venous or arterial catheters, 
endotracheal tubes, ventricular shunts, urinary catheters, and feeding tubes can 
insert pathogen into the body of the infant. Parenteral nutrition, exposure to pro-
longed courses of empiric antibiotics, H2-receptor blocker or proton pump inhibitor 
use can also result in increased risk for late-onset infections [13, 18, 37, 54, 55].
Once the bacterium has entered into the systemic circulation, the polysaccha-
ride capsule of the pathogen plays a key role in the survival of the pathogen in the 
hostile environment of the blood [15, 17, 56]. The polysaccharide capsule mediates 
resistance to complement-mediated lysis and phagocytosis by polymorphonuclear 
leukocytes and macrophages [15, 57]. The potential sites for bacteria entering the 
CNS are the cerebral microvascular endothelium of the arachnoid membrane and 
the choroid plexus epithelium where capillary endothelial cells are fused along the 
terminal edge by tight junctions [17]. The attachment of bacteria to microvascular 
endothelial cells and passage through the blood brain barrier (BBB) are promoted 
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by the interaction of specific bacterial factors with host receptors [57]. To facilitate 
crossing the BBB, Streptococcus pneumoniae interacts with cell wall phosphoryl-
choline and platelet activating factor receptor [8]. Streptococcus agalactiae uses the 
lipoprotein laminin-binding protein and K1 E Coli express type 1 fimbriae and 
the OmpA protein to contribute to the bacterium binding to cerebral endothelial 
cells [57–59]. The bacteria can cross the BBB transcellularly, paracellularly, and 
in infected phagocytes. Transcellular traversal occurs when the microorganism 
penetrates the cells without any evidence in the cells or intracellular tight-junction 
disruption [58]. Streptococcus pneumoniae, Streptococcus agalactiae, and E. coli can all 
cross the BBB via this mechanism [58]. Paracellular traversal occurs when micro-
organism penetrates between barrier cells [17]. L monocytogenes crosses the BBB 
by microbial penetration using transmigration within L monocytogenes-infected 
monocytes or myeloid cells across the BBB by a so-called Trojan horse mechanism 
[15, 58].
Once bacteria enter the cerebrospinal fluid, they are free to replicate and spread 
unchecked at least initially, as phagocytes, immunoglobulins, and complement 
components are excluded by the BBB. This bacterial multiplication goes on until 
bacteria die following the stationary growth phase or the exposure to the treatment 
with β-lactams that causes antibiotic-induced bacteriolysis. The subsequent release 
of subcapsular bacterial products such as peptidoglycan, lipoteichoic acids, lipopro-
teins, lipopolysaccharides, and bacterial DNA leads to an increased inflammatory 
response in the host [15, 59]. Many brain cells including astrocytes, glial cells, 
endothelial cells, ependymal cells, and resident macrophages can produce pro-
inflammatory and anti-inflammatory cytokines in response to bacterial replication 
and its components [60, 61]. Although this inflammation is needed to eliminate 
the bacteria and allow the host to recover, it is also a major cause of brain injury in 
meningitis [11, 61].
Neuronal injury in bacterial meningitis is caused by several mechanisms, which 
have been identified by experimental studies during the last years [15, 60–62]. 
Neuronal injury likely results from a combination of the following events: dysfunc-
tioning cerebral blood flow (increased BBB permeability, cerebral edema, vasospasm, 
vasculitis, cerebral venous thrombosis, and systemic hypotension), detrimental 
effects of inflammatory mediators (e.g., tumor necrosis factor-alpha, interleukin-1, 
and nitric oxide) and infiltrating cells (leukocytes, macrophages, and microglia), 
neurotoxicity (free radicals, proteases, and some microbial compounds), increased 
CSF outflow resistance, and excitatory amino acids, which finally lead to energy 
failure and cell death executed by caspases [15, 17, 60–63]. The mode of neuronal 
cell death in different regions of the brain depends on the strength and type of the 
noxious stimulus and may be a form of apoptotic, necrotic, or hybrid [62, 63]. For 
example, neuronal cell death occurs mostly as apoptosis in the dentate gyrus of the 
hippocampal formation, whereas it occurs mostly as necrosis due to focal ischemia in 
the cortex [15, 62, 63].
6. Risk factors
Since meningitis is most commonly a complication of bacteremia, the risk factors 
are similar to those that contribute to neonatal sepsis [4–6]. Risk factors for neonatal 
sepsis include maternal factors, neonatal host factors, and virulence of infecting 
organism. The most important neonatal factor is prematurity or low birth weight. 
Small preterm infants have a 3–10 times higher incidence of infection than full-term 
normal birth weight infants [4–6]. Immaturity of the immune system and diminishing 
transplacentally acquired maternal immunoglobulins in premature infants contribute 
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to increased risk of infections. Additionally, preterm infants often require prolonged 
hospital stay and so have one or more procedures such as parenteral nutrition, intuba-
tion, and central catheters that place them at risk for infection [18, 37]. Other host 
factors include hypoxia, acidosis, hyperbilirubinemia, hypothermia, galactosemia, 
indomethacin, lipid administration, and parenteral iron supplementation [37]. 
Maternal risk factors include GBS colonization or GBS bacteriuria, prolonged rupture 
of membranes of 18–24 hours or greater, chorioamnionitis, urinary tract infections, 
multiple pregnancies, and septic or traumatic delivery [13, 18, 37].
7. Clinical presentation
The earliest signs and symptoms of neonates with meningitis may be subtle 
and nonspecific, especially more problematic in premature infants [5]. The clinical 
presentation of neonatal meningitis is similar to those of neonatal sepsis without 
meningitis. Most commonly reported clinical features include temperature instabil-
ity (62%), irritability or lethargy (52%), and poor feeding or vomiting (48%) [18]. 
However, in preterm infants, respiratory decompensation consisting of an increased 
number of apnea and bradycardia episodes and increased oxygen requirement are 
prominent clinical signs [50]. Term infants are more likely to have fever (>37.2°C), 
whereas preterm infants more frequently have hypothermia (<36°C) [64]. Other 
findings associated with neonatal meningitis include respiratory distress, jaundice, 
diarrhea and hepatosplenomegaly. However, all these features could not help to 
establish an early diagnosis of meningitis [18].
Neurologic signs of neonatal meningitis include irritability, alteration in con-
sciousness, poor tone, tremors, seizures, high-pitched cry, twitching of facial or 
an extremity, focal signs including hemiparesis, gaze deviation, and cranial nerve 
deficits [4, 18]. Seizures are generally focal and seen in 40% of cases, and consider-
ing subtle ones is also possible [5, 18]. Since cranial sutures in the neonate are open 
and allow for expansion of the intracranial contents and for increasing head size, 
meningeal signs are not commonly seen. Bulging fontanelle occurs in about 25% of 
cases and nuchal rigidity in only 15% [28].
Early-onset neonatal infections are generally presented as sepsis or pneumonia, 
so meningitis is relatively less common. The signs of early-onset infection get to 
appear within the first 24–48 hours of life in 90% of affected cases [65]. However, 
late-onset sepsis, in addition to bacteremia, is frequently manifested as focal infec-
tions such as meningitis and osteomyelitis resulting from hematogenous seeding 
[11, 18]. Neonatal meningitis can complicate 14% of episodes of early-onset GBS 
sepsis and 54% of episodes of late-onset GBS sepsis [36], so the later condition is 
more likely to have specific signs of meningitis [28].
Lack of data on the timing of onset of features listed above makes it difficult 
for the early recognition of a baby with meningitis. Additionally, these features are 
likely to be affected by other factors such as gestational age, partial antibiotic treat-
ment, and postnatal age [6]. Classical meningitic signs such as convulsions, bulging 
fontanel, altered mental status, and nuchal rigidity are often late findings that 
are associated with a worse outcome [5, 6]. So, the timing of the onset of clinical 
features may be crucial for early recognition, prompt management and potentially, 
better outcome [6]. Although several useful clinical features were defined to predict 
meningitis in children, the most accurate combination of clinical features to raise or 
lower suspicion of meningitis is still unclear. Furthermore, small infants present-
ing nonspecific but concerning features such as fever, lethargy, poor feeding, or 
irritability, should be approached with a high index of suspicion regardless of how 
well they appear [66].
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Brain abscess, which can be presented by the findings of increased intracranial 
pressure, focal neurologic deficit, poor clinical response to antibiotic therapy, 
and new-onset focal seizures, occurs in about 13% of neonates with neonatal 
meningitis. However, the risk of brain abscess is increased in cases of meningitis 
caused by Citrobacter koseri (up to 75%), Serratia marcescens, Proteus mirabilis, 
and Enterobacter sakazakii. Therefore, when these pathogens are detected as the 
cause of the disease, neuroimaging should be performed even with no clinical 
indication [18, 28].
8. Diagnosis
Since the clinical signs and symptoms are nonspecific and similar to those 
seen in sepsis, CSF examination via lumbar puncture (LP) is essential to establish 
the diagnosis of bacterial meningitis and to identify the causative organism with 
antibiotic susceptibility testing [4]. LP should be performed in all neonates whose 
blood culture is positive and be considered in all neonates when sepsis is possible. 
As many as 40% of infants with meningitis who have a gestational age of ≥34 weeks 
do not have a positive blood culture at the time of their diagnosis [67]. Similarly, 
among VLBW infants who survived >3 days, one third of cases of meningitis have 
negative blood cultures [25]. Therefore, if LP is performed based on the presence of 
blood culture positivity, a significant number of cases of meningitis will be over-
looked [11]. This means that if sepsis or meningitis is suspected, performing LP is 
mandatory.
Debate continues as to whether an LP should be performed on all babies sus-
pected of sepsis or only on symptomatic babies. In the past, the LP had been a 
routine part of the evaluation of infants suspected of having sepsis, in conjunction 
with a complete blood cell count and blood cultures [17]. Meningitis in preterm 
infants with respiratory distress syndrome is unlikely, so an LP is not mandatory 
unless sepsis is suspected [68, 69]. Similarly, the yield of an LP from babies who 
are asymptomatic with or without maternal risk factors is likely to be very low 
[70]. However, during the first week of life, if the blood cultures yield a pathogenic 
organism or clinical features of sepsis exist, evaluation of CSF should be done 
[18]. It should be kept in mind that the use of intrapartum antibiotics makes blood 
culture results unreliable. In every infant older than 1 week, an LP is indicated as 
a routine part of the work-up for sepsis [17]. Performance of the LP is sometimes 
delayed due to cardiorespiratory instability, extreme prematurity with the risk of 
intraventricular hemorrhage, or thrombocytopenia, resulting in delay in diagnosis 
and prolonged and possibly inappropriate antibiotic use [25]. If it is not possible to 
perform an LP in the infant with presumed sepsis and meningitis, antimicrobials in 
doses sufficient for the treatment of meningitis should be initiated immediately fol-
lowing obtaining blood for culture. When the infant is stabilized, even if antibiotic 
therapy is being taken for several days, LP should be performed. A delayed LP is still 
likely to show the presence of CSF pleocytosis and abnormal CSF chemistry and 
thus confirms the diagnosis of meningitis, although CSF culture may be negative 
[4, 11, 23]. In such cases, real-time polymerase chain reaction (PCR) may have an 
important role as a better diagnostic tool, although its routine use in the context of 
neonatal infection is currently limited [11, 71].
Infants with suspected bacterial meningitis or late-onset sepsis should undergo 
a full laboratory evaluation consisting of a complete blood count with differen-
tial, blood culture, a urine analysis and culture (useful only after the third day 
of life), and lumbar puncture to examine the CSF [50]. Ancillary tests such as 
complete blood cell count, C-reactive protein, interleukin-6, and procalcitonin 
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have suboptimal sensitivity and specificity for the diagnosis of neonatal sepsis, but 
these diagnostic tests may be useful in supporting the diagnosis of infection as well 
as determining the length of therapy when they are serial abnormal and accompa-
nied by clinical features of infection [23, 37, 50].
CSF culture is the gold standard method for diagnosing bacterial meningitis. 
So, it is important to perform an LP early in the course of illness, ideally before 
the administration of antibiotic therapy [72]. However, infants may be exposed to 
intrapartum or empiric antibiotics before performing an LP, making CSF param-
eters helpful in determining the likelihood of meningitis, because of the possibility 
of false CSF culture negativity in those with meningitis [4].
9. Examination of cerebrospinal fluid
Although examination of the CSF is highly important in supporting the diag-
nosis of meningitis, interpretation of CSF findings can be challenging in newborn 
infants [72]. Values for both the cellular and chemical parameters of CSF are 
different for neonates than for older infants and children, and also vary according 
to gestational age, birth weight, and chronologic age (Table 2) [73–77]. The cell 
content and protein concentration in the CSF of a healthy neonate are higher than 
those of older infants, whereas CSF glucose levels may be as low as 30 mg/dl in 
Age [Ref.] WBC/mm3 Protein (mg/dL) Glucose (mg/dL)
Term neonates evaluated in the nursery setting† [73]
≤7 days (n: 130) Median (IQR): 
3 (1–6); 95th 
percentile: 23
Median (IQR):  
78 (60–100); 95th 
percentile: 137
Median (IQR): 
50 (44–56); 5th 
percentile: 35
8 days to 6 months  
(n: 140)*
Median (IQR): 
2 (1–4); 95th 
percentile: 32
Median (IQR): 
57 (42–77); 95th 
percentile: 158
Median (IQR): 
52 (45–64); 5th 
percentile: 38
Term neonates evaluated in the emergency department setting‡
≤28 days (n: 3467) [74] Mean: 5.5; 95th 
percentile: 16
Mean (±SD): 69.9 
(±25.7); upper bound: 
127
Mean (±SD): 45.7 
(±8.0); lower bound: 
25
<28 days (n: 278) [75] Mean (range): 6.1 
(0–18.0)
Mean (range): 75.4 
(15.8–131.0)
Mean (range): 45.3 
(30.0–61.0)
28–56 days (n: 318) [75] Mean (range): 3.1 
(0–8.5)
Mean (range): 58.9 
(5.5–105.5)
Mean (range): 48.0 
(30.5–65.5)
Preterm very low birth weight (<1500 g) neonates
≤7 days (n: 88) [76] Mean (range): 7.1 
(0–30)
Mean (range): 144 
(51–270)
Mean (range): 50.4 
(11–138)
≤28 days (n: 45) [77] Mean (range): 5 
(0–44)
Mean (range): 148 
(54–370)
Mean(range): 67 
(33–217)
WBC: white blood cell count; SD: standard deviation; IQR: interquartile range; CSF: cerebrospinal fluid; neonatal 
intensive care unit; and n: number of cases. 
†CSF was obtained from infants evaluated for sepsis in the NICU setting.
*In this study, only a small proportion of infants were aged >28 days.
‡CSF was obtained in the emergency department during evaluation for possible infection; infection was excluded 
by sterile cultures (CSF, blood, and urine). Infants with positive polymerase chain reaction for enterovirus were also 
excluded.
Table 2. 
Characteristics of cerebrospinal fluid in term and preterm neonates without bacterial meningitis.
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term infants and as low as 20 mg/dl in preterm infants [77]. CSF protein is higher 
in preterm versus term infants. Moreover, the values of CSF parameters in neonates 
with and without confirmed meningitis may overlap [72].
Characteristic CSF findings of neonatal bacterial meningitis include poly-
morphonuclear pleocytosis, hypoglycorrhachia, and increased protein concen-
trations [8]. Cerebrospinal fluid white blood cell (WBC) counts of >21 cells/
mm3 in infants with gestational age ≥ 34 weeks have a sensitivity and specificity 
of approximately 80% to suggest confirmed meningitis. However, this cut off 
may be resulted in a missed diagnosis in 13% of infants with confirmed men-
ingitis, since neonatal meningitis can also occur with normal CSF parameters 
without bacteremia [4, 67]. If CSF is examined so early, before meninges are 
not inflamed enough, CSF findings may not be definitive for bacterial menin-
gitis, requiring the repeat LP 24–48 hours later. In a neonate, a CSF WBC count 
of >20 cells/mm3 is consistent with meningeal inflammation, and suggests 
bacterial meningitis [4]. The number of WBCs in the CSF is higher in neonates 
with meningitis caused by Gram-negative bacteria than those caused by Gram-
positive bacteria [78], and can be up to thousands, with predominantly poly-
morphonuclear leukocytes in the early course of the disease [18, 28]. The level 
of CSF protein is considered a poor predictor of neonatal meningitis because 
of considerable overlap of values between infants with and without confirmed 
meningitis [4, 67]. In general practice, a CSF protein of 170 mg/dl in preterm 
and > 100 mg/dl in term infants is interpreted in favor of neonatal bacterial men-
ingitis. However, caution should be employed when interpreting CSF parameters 
in preterm infants [79, 80].
Antibiotic treatment before the LP is a common practice because LPs are not 
being performed in all cases [5]. When patients with true meningitis are exposed to 
antibiotics for up to 24–36 hours, CSF WBC values remain elevated without signifi-
cance. However, CSF protein values decrease but still remain higher than normative 
values, whereas CSF glucose values show rapid normalization [72, 81]. So, because 
of limited impact of pretreatment antibiotics on CSF WBC, it does not prevent 
the diagnosis of meningitis up to 24 hours. Additionally, once CSF is obtained, 
the sample should be analyzed as soon as possible, otherwise a delay in laboratory 
analysis may result in the decline in measured WBC [82].
Gram stain of CSF is useful in providing an early presumptive etiologic diag-
nosis, especially Gram-negative bacteria, since the culture of CSF can take up to 
48 hours [6]. Its positivity rates depend on the CSF concentration of bacteria, so the 
absence of the organism on Gram stain does not exclude meningitis [8]. In cases of 
meningitis caused by L. monocytogenes, Gram stain is frequently negative due to the 
low number of bacteria in the CSF [17].
Traumatic LP is defined as the presence of blood in the CSF obtained, and 
occurs very frequently in neonates, with reported incidences ranging from 35 to 
46% [72]. This condition makes the interpretation of CSF results more compli-
cated. Adjustment of CSF WBC in traumatic LPs does not improve the diagnosis 
of neonatal bacterial meningitis, and adjustment can result in loss of sensitivity 
with marginal gain in specificity [72]. CSF protein may be elevated in the presence 
of blood contamination from a traumatic LP [83]. It may be useful to repeat the LP 
24–48 hours later, so that normal WBC can exclude bacterial meningitis, but fre-
quently it is inconclusive. Neonates in whom the LP is traumatic should be treated 
with antibiotic presumed meningitis, until results of CSF culture are available.
Among nonculture tests of CSF, the PCR has been useful in the identification 
of infecting bacteria including Streptococcus pneumoniae, E coli, GBS, S aureus, 
and L monocytogenes, with higher detection rate of any CSF pathogen compared 
with traditional cultures (72% vs. 48%) in patients with antibiotic administration 
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[71]. However, the use of PCR is limited to selected cases for now, and before used 
routinely, requires further researches and institutional facilities [84, 85]. Since PCR 
neither detects all causes of CNS infection nor provides any information on antimi-
crobial susceptibility, it should be used in conjunction with standard microbiologic 
tests. A number of CSF biomarkers such as tumor necrosis factor a, interleukin (IL) 
1b, IL-6, IL-8, IL-10, IL-12, IL-17, C-reactive protein, procalcitonin, and lipocalin 2 
have been examined for differentiating bacterial meningitis from viral meningitis 
and noninfectious origins, and the results have been encouraging [8, 86]. However, 
the validity and use of these biomarkers in clinical practice have been limited, and 
the interpretation of the results of these assays should be done with caution.
10. Differential diagnosis
Besides sepsis and other specific infections, symptoms and signs may be due 
to noninfectious conditions such as cardiac, pulmonary, gastrointestinal, and 
metabolic disorders [11, 18]. Disorders mimicking the neurological features of 
meningitis include intracranial hemorrhage, ischemic stroke, hypoxic–ischemic 
encephalopathy, injuries, and inborn errors of metabolism [11, 18]. Conditions 
where CSF culture is negative despite CSF changes include infectious and non-
infectious causes of aseptic meningitis, partially treated bacterial meningitis, 
parameningeal infected focus such as abscess, and intraventricular hemorrhage. 
Since some of the pathogens that cause aseptic meningitis have specific therapy, 
a comprehensive evaluation including viral, anaerobic, mycoplasma, and fungal 
cultures, antigen detection, PCR, and serology should be performed [18]. Elevated 
CSF protein values and leukocyte counts and hypoglycorrhachia may develop in 
preterm infants after intraventricular hemorrhage. Many nonpyogenic congenital 
infections (toxoplasmosis, cytomegalovirus, herpes simplex virus, and syphilis 
producing aseptic meningitis) can also produce alterations in CSF protein values 
and leukocyte counts. [18, 50].
11. Antimicrobial treatment
Eradication of the infecting pathogen from the CSF is entirely dependent on 
antimicrobial therapy which should be initiated as soon as possible after the evalua-
tion which is suggestive of bacterial meningitis [8]. Since clinical presentation may 
be subtle and nonspecific and the outcome may be devastating, a low threshold 
for initiating antimicrobial therapy is necessary without knowledge of the specific 
pathogen [6]. Decisions on which antibiotics to use empirically are designed to 
cover the likely pathogens based on the age of the patient (e.g., early-onset  
meningitis), specific risk factors, data regarding pathogens and their susceptibility 
within nursery, and the ability to penetrate the CSF [8, 87, 88]. The initial choice 
of intravenous antibiotics for neonates suspected of having meningitis must cover 
both Gram-positive and Gram-negative organisms [89]. Efficient elimination of 
bacteria depends also on the relationship between the concentration of antibiotic 
in the CSF and the minimal bactericidal concentration (MBC) for the infecting 
pathogen [17]. Then, antibiotics are modified according to culture and antibiotic 
susceptibility tests, as indicated.
Initial empirical therapy for early-onset bacterial meningitis must include a com-
bination regimen containing ampicillin and an aminoglycoside (e.g., gentamicin) 
to cover GBS, E coli, and L monocytogenes, whereas a regimen including a third- 
generation cephalosporin (e.g., cefotaxime) is preferred when meningitis resulting 
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from a Gram-negative organism is strongly suspected [8, 18]. This empirical anti-
microbial therapy should be continued until the pathogen and its antibiotic sus-
ceptibility are identified. Since eradication of Gram-negative bacteria from CSF is 
often delayed and high rates of ampicillin resistance among E. coli isolates have been 
reported, cefotaxime is the agent of choice, thanks to its higher CSF bactericidal 
activity [89, 90]. However, when the use of cefotaxime is routine, rapid emergence 
of cephalosporin-resistant strains, especially Enterobacter cloaca, Klebsiella pneu-
moniae, Pseudomonas aeruginosa, E coli, and Serratia species, can occur (via inducible 
beta-lactamases), even during therapy [91–94]. It is recommended that such infec-
tions should be treated with a carbapenem (usually meropenem), in combination 
with an aminoglycoside, since carbapenem resistance has recently emerged among 
Gram-negative bacilli [50, 95, 96]. Therefore, meningitis caused by Gram-negative 
bacteria need to be closely monitored, which includes repeating LP for documenta-
tion of CSF sterility and brain imaging studies with clinical indications [8, 97].
There is a synergy for ampicillin and gentamycin in the treatment of meningitis 
caused by GBS, and this combination should be continued until sterility of the CSF 
has been documented [17]. Afterwards, single therapy with penicillin or ampicillin 
should be used for 14 days [97]. Although GBS is also susceptible to cephalosporins, 
the use of the narrower agent, like penicillin, will minimize any potential impact on 
antibiotic resistance among other pathogens [87]. Infection caused by L monocyto-
genes and Enterococcus should be treated with ampicillin and gentamycin, since both 
are resistant to cephalosporins [17, 87]. When the CSF has been sterilized and the 
patient has improved clinically, ampicillin alone can be used to complete therapy. 
Because of high rate of ampicillin resistance among E. coli and other Gram-negative 
organisms, a combination of cefotaxime (or ceftazidime in the case of P. aeruginosa) 
and an aminoglycoside, usually gentamicin, is preferable. Once sterility of the CSF 
is documented, the aminoglycoside can be discontinued and the appropriate beta-
lactam should be continued for a minimum of 21 or 14 days after the CSF is sterile, 
whichever is the longest [17–19, 87, 97].
Initial empirical therapy for late-onset bacterial meningitis usually depends 
on whether the infection is community or hospital acquired. For babies admitted 
from home, an empiric antibiotic combination of amoxicillin or ampicillin and 
cefotaxime is likely to provide excellent cover for possible pathogens, with good 
CSF penetration [5, 11, 88]. In areas where there are high rates of cephalosporins 
resistance among Streptococcus pneumonia, initial treatment of meningitis may 
include high doses of third-generation cephalosporins in association with vancomy-
cin before the results of antibiotic susceptibility [98]. Although the implementation 
of pneumococcal vaccination led to a near disappearance of vaccine serotypes resis-
tant to β-lactams, it also contributed to the emergence of the 19A serotype, which 
was particularly resistant to antibiotics [98]. Some community-based studies from 
developing countries have reported increasing resistance, particularly of Gram-
negative organism to first-line and even second-line antibiotics [88]. Therefore, in 
the choice of empirical antibiotics, the resistance pattern of possible pathogens in 
the community should also be considered.
For babies already in hospital or discharged recently from hospital, initial 
antimicrobial therapy should be chosen according to the pathogen commonly seen 
in that particular nursery and their susceptibility pattern [11]. There are various 
factors that may influence the likely spectrum of causative pathogens, especially 
their risk of unusual or multidrug resistant bacteria [5, 18]. These include prior 
exposure to broad-spectrum antibiotics, the presence of central venous lines, ven-
triculoperitoneal shunt, or ventricular reservoir, parenteral nutrition, and their risk 
of acquiring infections through nosocomial transmission [5, 55, 99, 100]. Therefore, 
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empirical therapy may include ampicillin (if GBS, L monocytogenes or enterococci 
are suspected), nafcillin, or vancomycin and an aminoglycoside, and cefotaxime, 
or meropenem, depending on the predominant pathogen seen in the neonatal unit 
[50, 97]. Meningitis with organisms such as CNS, which is more common in neo-
nates requiring prolonged hospitalization, need for central venous catheters, and 
surgical manipulations or placement of a ventriculoperitoneal shunt due to intra-
ventricular hemorrhage and hydrocephalus [55, 100], can be treated with nafcillin 
or vancomycin, assuming that the isolate is susceptible [18, 50, 101]. The duration 
of therapy is generally 14–21 days after CSF sterilization, with removal of any 
foreign body if possible [18, 50, 101]. Meropenem is recommended for treatment of 
neonatal meningitis that is caused by MDR Gram-negative organisms, although it is 
approved for use only in infants aged older than 3 months for bacterial meningitis 
or complicated intra-abdominal infections due to limited data on meropenem use in 
neonates [97, 102]. Metronidazole is the treatment of choice for infection caused by 
Bacteroides fragilis and other anaerobic organisms [18, 50].
The recommended antimicrobial treatment based on causative organism and dos-
age of common antibiotics used for neonatal meningitis are provided in Tables 3 and 4 
[4, 50, 87, 97, 103, 104].
Although the intraventricular or intrathecal route of administration of antibiot-
ics is able to achieve higher antibiotic concentrations in the CSF and eliminate the 
bacteria more quickly, intraventricular antibiotics in combination with intravenous 
antibiotics resulted in a three-fold increased relative risk for mortality compared to 
standard treatment with intravenous antibiotics alone and should be avoided [105]. 
However, it remains an option in patients who already have a ventricular drain in 
place and persistently positive CSF cultures [101].
In the cases of neonates with bacteremia and CSF findings indicative of men-
ingitis with negative CSF culture (obtained before or after antibiotic therapy), the 
antimicrobial therapy should be continued with meningeal doses as if they have 
proven bacterial meningitis [97, 106].
The role of routinely repeating CSF evaluation during treatment in a neonate 
with confirmed meningitis is controversial. Some experts recommended that an 
LP should be repeated routinely at 48–72 hours after initiation of appropriate 
antimicrobial therapy to document CSF sterilization, as persistence of posi-
tive cultures despite treatment may result in a greater risk of complications and 
poor outcomes [87, 107]. Gram-positive bacteria usually clear rapidly (within 
24–48 hours) from the CSF, whereas Gram-negative bacteria may persist for 
several days in severe cases [18, 97]. A delayed clearance of a Gram-negative 
organism may be an indication for antimicrobial resistance and prompts a change 
in therapy or diagnostic neuroimaging showing a purulent focus of the disease 
such as an emphysema, obstructive ventriculitis, or brain abscess requiring addi-
tional intervention or increased duration of antimicrobial therapy [18, 97, 108]. 
Additionally, performing repeating LP is also reasonable for discontinuing combi-
nation therapy. Delayed sterilization of the CSF is associated with an increased risk 
of poor outcome [17, 87, 109]. So, a repeat LP may have therapeutic and prognostic 
significance. Conversely, some experts recommend a repeat LP only if the patient 
does not exhibit a satisfactory clinical response by 24–72 hours after initiation of 
antimicrobial therapy or show a complicated clinical course, including seizures, 
abnormal neuroimaging, or prolonged positive CSF cultures [4, 110]. The decision 
of whether to perform an LP before completion of therapy in the neonates with 
meningitis caused by GBS, L. monocytogenes, and Gram-negative bacteria can be 
based on clinical course including seizures, significant hypotension, prolonged 
positive CSF cultures, and abnormal neuroimaging [50].
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Causative organism Recommended therapy Comment
Initial therapy, CSF 
abnormal but organism 
unknown
Ampicillin IV and gentamicin 
IV, IM and cefotaxime IV
Cefotaxime is added if meningitis is 
suspected or cannot be excluded.
Alternatives to ampicillin in nursery-
acquired infections: vancomycin or 
nafcillin.
Alternatives to cefotaxime: ceftazidime, 
cefepime, or meropenem (limit use to 
multidrug-resistant organisms in nursery 
(e.g., extended-spectrum b-lactamase-
producing organisms).
Bacteroides fragilis spp. Metronidazole IV Alternative: meropenem.
Coliform bacteria (E coli, 
Klebsiella sp., Enterobacter 
sp., Citrobacter sp., and 
Serratia sp.)
Cefotaxime IV, IM, and 
gentamicin
Discontinue gentamicin when clinical and 
microbiologic response is documented. 
Alternative: ampicillin if organism is 
susceptible; meropenem or cefepime for 
multiresistant organisms.
Lumbar intrathecal or intraventricular 
gentamicin usually not beneficial.
Chryseobacterium 
meningosepticum
Vancomycin IV and rifampin 
IV, PO
Alternatives: clindamycin and 
ciprofloxacin
Group A streptococcus Penicillin G or ampicillin IV
Group B streptococcus Ampicillin or penicillin G IV 
and gentamicin IV, IM
Discontinue gentamicin when clinical and 
microbiologic response is documented
Enterococcus spp. Ampicillin IV, IM, and 
gentamicin IV, IM; for 
ampicillin-resistant organisms: 
vancomycin and gentamicin
Gentamicin only if synergy documented
Other streptococcal 
species
Penicillin or ampicillin IV, IM
Gonococcal Ceftriaxone IV, IM or 
cefotaxime IV, IM
Duration of therapy uncertain 
(5–10 days?)
Haemophilus influenzae Cefotaxime IV, IM Ampicillin if β-lactamase negative
Listeria monocytogenes Ampicillin IV, IM, and 
gentamicin IV, IM
Gentamicin is synergistic in vitro with 
ampicillin but can be discontinued when 
sterilization is achieved
Staphylococcus epidermidis 
(or any coagulase-
negative staphylococci)
Vancomycin IV Add rifampin if cultures are persistently 
positive
Alternative: linezolid
Staphylococcus aureus MSSA: nafcillin IV; MRSA: 
vancomycin IV
Gentamicin may provide synergy; 
rifampin if cultures are persistently 
positive. Nafcillin is superior to 
vancomycin for treatment of methicillin-
sensitive S aureus
Pseudomonas aeruginosa Ceftazidime IV, IM and 
aminoglycoside IV, IM
Meropenem or cefepime are suitable 
alternatives
Ureaplasma spp. Doxycycline IV or 
azithromycin IV
Alternatives: ciprofloxacin
Mycoplasma hominis Clindamycin or doxycycline IV Alternatives: ciprofloxacin
IM, intramuscularly; IV, intravenously; MSSA: methicillin-susceptible S. aureus; MRSA: methicillin-resistant  
S. aureus; PO, periorally. 
†Adapted from Ref. [50].
Table 3. 
Recommended antimicrobial treatment for neonatal bacterial meningitis.†
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Antibiotic Susceptible 
bacteria
Dose per kilogram Comments
Body 
weight ≤ 2000 g
Body 
weight > 2000 g
Penicillin G GBS 100,000 U
≤7d old, every 12 h
8–28 d old, every 
8 h
100,000 U
≤7 d old, every 8 h
8–28 d old, every 
6 h
Monotherapy 
acceptable if GBS 
is confirmed by 
culture and clinical 
improvement is 
observed
Ampicillin GBS
L. 
monocytogenes 
Enterococcus 
sp.
50 mg
≤7d old, every 12 h
8–28 d old, every 
8 h
50 mg
≤7d old, every 12 h
8–28 d old, every 
8 h
17–78% of E. coli 
isolates are resistant
Poor CNS penetration
Gentamicin/
Amikacin
E. coli
Klebsiella sp.
Enterobacter 
sp.
Pseudomonas 
sp.
Citrobacter 
sp.
Serratia sp.
5 mg/15 mg
≤7d old, every 48 h
8–28 d old, every 
36 h
4 mg/15 mg
≤7d old, every 24 h
8–28 d old, every 
24 h
Poor CNS penetration
Synergistic effect with 
ampicillin in treatment 
of L. monocytogenes
Pseudomonas sp. may 
require combination 
therapy with a second 
agent
Require therapeutic 
drug monitoring
Cefotaxime E. coli
Klebsiella sp.
Enterobacter 
sp.
Citrobacter 
sp.
Serratia sp.
50 mg
≤7d old, every 12 h
8–28 d old, every 
8–12 h
50 mg
≤7d old, every 12 h
8–28 d old, every 
8 h
Good CNS penetration
Used instead of 
gentamicin in cases 
of suspected or 
confirmed meningitis
Not active against 
L. monocytogenes or 
Enterococcus sp.
Meropenem E. coli 
Klebsiella sp.
Enterobacter 
sp.
Citrobacter 
sp.
Serratia sp.
Pseudomonas 
sp.
40 mg
≤14 d old, every 
12 h
14–28 d old, every 
8 h
40 mg
≤14 d old, every 
8 h
14–28 d old, every 
8 h
Good CNS penetration
Limit use to multidrug 
resistant organisms 
(e.g., extended-
spectrum beta-
lactamase-producing 
organisms)
Vancomycin Coagulase-
negative 
staphylococci
S. aureus 
Enterococcus 
sp.
15 mg
≤7d old, every 24 h
8–28 d old, every 
12 h
15 mg
≤7d old, every 12 h
8–28 d old, every 
8 h
Variable CNS 
penetration
Effective against 
methicillin-resistant 
S. aureus
Requires therapeutic 
drug monitoring
Nafcillin Methicillin-
sensitive S. 
aureus
50 mg
≤7d old, every 12 h
8–28 d old, every 
8 h
50 mg
≤7d old, every 8 h
8–28 d old, every 
6 h
Good CNS penetration
Superior to 
vancomycin for 
treatment of 
methicillin-sensitive 
S. aureus
GBS, group B streptococcus; CNS, central nervous system; g, gram; d, day. 
†Adapted from Refs. [4, 87, 97, 102, 103].
Table 4. 
Dosage of antibacterial drugs commonly used to treat neonatal meningitis.†
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12. Neuroimaging
Neuroimaging is recommended to assist in defining the potential complica-
tions of neonatal meningitis [50, 87]. Ultrasonography, which is a safe, conve-
nient, and noninvasive method, can be done at bedside early in the course of the 
disease. It provides rapid and reliable information regarding ventricular size, 
the presence of hemorrhage, and development of hydrocephalus [111, 112]. It 
is also useful to detect periventricular white matter injury which may initially 
be manifested by increased periventricular echogenicity and later by cystic 
periventricular leukomalacia, ventriculitis, echogenic sulci, and extracerebral 
fluid collections [113, 114]. Computed tomography is rapid and easy imag-
ing modality, but carries the risk of neonatal brain to radiation. It is useful to 
provide information on whether the course of meningitis has been complicated 
by hydrocephalus, brain abscess, or subdural collection. These findings may 
have a role in decision-making for potential neurosurgical interventions or 
duration of antimicrobial therapy [28, 87]. Magnetic resonance imaging (MRI) 
is the best currently available modality for evaluation of the neonatal brain 
[115]. It provides information on the status of white matter, cortex, subdural 
and epidural spaces, and even the posterior fossa, when performed either early 
or late in the course of the disease. It is useful to document the distribution 
pattern, severity, and complications of the disease [115, 116]. It has also been 
used in providing the best prognostic information [28]. For these reasons, it is 
recommended that at least one brain MRI should be performed on every case 
of neonatal meningitis, especially those caused by organisms that have a pro-
pensity for formation of intracranial abscesses [17, 28, 87]. Ideally in all cases, 
MRI scans must include pre-contrast and post-contrast-enhanced T1-weighted 
and T2-weighted images in at least two perpendicular planes. Fluid attenuated 
inversion recovery (FLAIR) sequence and diffusion weighted imaging (DWI) 
are preferred whenever purulent collections are suspected because of their high 
sensitivity in showing pus accumulation [115].
13. Adjunctive therapy
Bacterial meningitis in the newborn infant is characterized by high risk of 
mortality and serious neurological sequelae among most survivors. It is believed 
that most sequelae occur as a result of neural injury during the acute inflamma-
tory process that characterizes bacterial meningitis. Given that corticosteroids 
may help attenuate the acute inflammatory process, adjuvant corticosteroid 
treatment in children with bacterial meningitis may reduce mortality in S pneu-
moniae meningitis but not in H. influenzae nor N. meningitidis meningitis, and 
severe hearing loss among children with H. influenza meningitis but not among 
those with meningitis due to non-Haemophilus species [117]. Additionally, these 
beneficial effects of corticosteroids have been reported in the reports from high-
income countries, but not in those from low-income countries, probably due to 
the types of pathogens prevalent in the developing world, delay in the initiation 
of appropriate antibiotic treatment, partial treatment involving indiscriminate 
antibiotic use outside of hospitals, or lack of facilities [7]. A few studies suggest 
that some reduction in death and hearing loss is evident when adjunctive steroids 
are used in the treatment of neonatal meningitis, but experimental animal studies 
reported that adjunctive treatment with corticosteroid is associated with an 
increase in hippocampal neuronal apoptosis [118]. In conclusion, it should not be 
used routinely in the treatment of neonatal meningitis due to limited data [119]. 
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Similarly, the limited studies showed that glycerol, when used as osmotic therapy, 
may reduce neurological deficiency and deafness in adults and children with acute 
bacterial meningitis [120], but it is not currently recommended in neonates with 
bacterial meningitis [4].
14. Complications
Short-term neurological complication of neonatal bacterial meningitis includes 
cerebral edema, increased intracranial pressure, ventriculitis, cerebritis, hydroceph-
alus, brain abscess, cerebrovascular disease including ischemic arterial stroke and 
cerebral venous thrombosis, and subdural effusion or empyema [18, 121]. Cerebral 
edema results from vasogenic changes, cytotoxic cell injury, and occasionally inap-
propriate antidiuretic hormone secretion [28]. Ventriculitis, which occurs in about 
20% of neonates with meningitis caused by Gram-negative organisms, is a result of 
bacterial entry into the CNS through the choroid plexus [28, 121, 122]. Inflammatory 
exudate covers the epidermal lining and the choroid plexus, disrupts ependymal 
lining, and causes subependymal venous thrombosis and eventually necrosis [28]. It 
is usually associated with obstruction of CSF outflow [121]. Cerebritis results from 
extension of exudate along perivascular space [18, 28]. Hydrocephalus, which occurs 
in approximately one-quarter of neonates with meningitis, develops as a result of 
fibrous inflammatory exudate obstructing CSF flow through the ventricular system 
or dysfunction of arachnoid villi [18, 28, 122, 123]. Cerebral infarction occurs in 
approximately 30% of neonates with meningitis and is frequently hemorrhagic 
[28, 124]. The mechanisms leading to cerebrovascular complications in bacterial 
meningitis are not completely understood and likely are multifactorial [15, 62]. 
Brain abscesses, which occur in approximately 10 percent of patients with neonatal 
meningitis, may result from a hematogenous spread of microorganism into infarcted 
brain, or by local spread [28, 121]. Subdural effusions occur in approximately 11% of 
neonates with meningitis and rarely cause clinically significant finding and lead to 
empyema. [28, 121].
Neonates with bacterial meningitis should be monitored for signs of these com-
plications throughout their treatment. It must be suspected when there is a failure 
to respond clinically and microbiologically to appropriate antimicrobial therapy, 
or a focal neurologic deficit, or new-onset seizures, especially focal seizures, or 
when there are signs of increased intracranial pressure such as bulging fontanelle, 
accelerated head growth, bradycardia, hypertension, and separation of the cranial 
sutures [18, 121]. Acute deterioration in an otherwise stable neonate with meningi-
tis can occur if the abscess ruptures into ventricular system or subarachnoid space 
[28, 121]. In case of suspicion regarding these complications, additional evaluation 
including neuroimaging studies, neurosurgical consultation, and prolonged dura-
tion of antimicrobial treatment may be required.
15. Outcome
In developed countries, the rate of mortality from bacterial meningitis among 
neonates has declined substantially from nearly 50% in the 1970s to figures cur-
rently ranging from 10 to 15% [4, 5, 26–29]. In developing countries, the mortality 
rate is much higher at 40–58% [7]. Mortality is higher among preterm infants, in 
cases with meningitis caused by microorganism that causes vasculitis and brain 
abscess and in late-onset cases [26–29]. Risk factors involved in higher mortality 
rate and severe disability are low birth weight or prematurity, history of symptoms 
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for >24 hours before admission, leukopenia (<5000/mm3) and neutropenia  
(<1000/mm3), seizures lasting longer than 72 hours, coma, focal neurologic defi-
cits, ventilator support, the need for inotropes, higher CSF protein level,  
and delayed sterilization of the CSF [4, 5, 24, 26–29, 109, 121–125].
Long-term complications in survivors are mental and motor disabilities 
including mental retardation, learning disabilities, cerebral palsy, and behavioral 
problems, seizures, hydrocephalus, language disorders, hearing loss, and impaired 
visual acuity [4, 5, 14, 27]. Approximately 20% of survivors have severe disability 
and another 35% have mild to moderate disability [4, 5, 122]. Neonatal meningitis 
caused by S. pneumoniae and Gram-negative bacteria carries a worse prognosis  
[24, 50, 122, 126]. All infants experienced with bacterial meningitis should be fol-
lowed long-term for development of neurological sequelae.
16. Prevention
Intrapartum antibiotic prophylaxis for GBS colonized women or based on the 
presence of clinical risk factors is efficacious against early onset GBS disease but 
has no impact on late-onset disease, when most GBS meningitis occurs [5, 127].  
The incidence of late-onset GBS disease remains unaffected by IAP use [33, 35]. 
Vaccines against GBS can reduce the number of missed opportunities due to 
various reasons. So, maternal immunity to the most common serotypes of GBS 
(serotypes Ia, Ib, and III) can be transferred passively to the fetus and protect 
against invasive infection in infancy due to covered serotypes [128]. Clinical trials 
of a trivalent GBS vaccine are encouraging in this regard. In the case of pneumo-
coccal meningitis, the 10- and 13-valent conjugate vaccines may be protective for 
infants aged <3 months [5].
The prevention of the spread of the pathogens responsible for neonatal sepsis 
and meningitis also has an impact on disease burden [6]. Several interventions, 
which can be introduced at the community level, with prevention strategies applied 
during the antenatal, intrapartum, and early neonatal period, will reduce the 
number of early-onset diseases [16, 129]. Prevention of nosocomial infections is 
based on strategies that aim to limit susceptibility to infections by enhancing host 
defenses, interrupting transmission of organisms by healthcare workers, and by 
promoting the judicious use of antimicrobials [130].
17. Summary
Bacterial meningitis is associated with significant morbidity and mortality in the 
neonatal population. Although overall incidence and mortality have declined over 
the last several decades, morbidity associated with neonatal meningitis remains 
unchanged. Prompt diagnosis and treatment are mandatory to improve both short- 
and long-term outcomes. CSF culture obtained via LP is the gold-standard method 
for the diagnosis of meningitis, which is the key to rapid institution of effective 
antimicrobial therapy. Prevention strategies, adjunctive therapies, improved 
diagnostic strategies, and development of vaccines may further reduce the burden 
of this devastating disease.
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